» Articles » PMID: 16492763

Theileria Parva Candidate Vaccine Antigens Recognized by Immune Bovine Cytotoxic T Lymphocytes

Abstract

East Coast fever, caused by the tick-borne intracellular apicomplexan parasite Theileria parva, is a highly fatal lymphoproliferative disease of cattle. The pathogenic schizont-induced lymphocyte transformation is a unique cancer-like condition that is reversible with parasite removal. Schizont-infected cell-directed CD8(+) cytotoxic T lymphocytes (CTL) constitute the dominant protective bovine immune response after a single exposure to infection. However, the schizont antigens targeted by T. parva-specific CTL are undefined. Here we show the identification of five candidate vaccine antigens that are the targets of MHC class I-restricted CD8(+) CTL from immune cattle. CD8(+) T cell responses to these antigens were boosted in T. parva-immune cattle resolving a challenge infection and, when used to immunize naïve cattle, induced CTL responses that significantly correlated with survival from a lethal parasite challenge. These data provide a basis for developing a CTL-targeted anti-East Coast fever subunit vaccine. In addition, orthologs of these antigens may be vaccine targets for other apicomplexan parasites.

Citing Articles

Comparative transcriptional analysis identifies genes associated with the attenuation of Theileria parva infected cells after long-term in vitro culture.

van der Heijden E, Lefevre L, Gossner A, Tzelos T, Connelley T, Hassan M Sci Rep. 2024; 14(1):8976.

PMID: 38637584 PMC: 11026401. DOI: 10.1038/s41598-024-59197-y.


Conservation and variation in the region of the Theileria parva p104 antigen coding gene used for PCR surveillance of the parasite.

Obara I, Makori P, Sibeko K, Bishop R, Nijhof A, Mwamuye M Parasitol Res. 2023; 122(6):1381-1390.

PMID: 37081209 PMC: 10172223. DOI: 10.1007/s00436-023-07838-y.


The antigen recognition portion of African buffalo class I MHC is highly polymorphic, consistent with a complex pathogen challenge environment, and the 3' region suggests distinct haplotype configurations.

Obara I, Nijhof A, Atimnedi P, Mijele D, Nanteza A, Elati K Immunogenetics. 2022; 75(2):115-132.

PMID: 36512055 PMC: 10039833. DOI: 10.1007/s00251-022-01287-0.


Immunopeptidomic Analysis of BoLA-I and BoLA-DR Presented Peptides from Infected Cells.

Connelley T, Nicastri A, Sheldrake T, Vrettou C, Fisch A, Reynisson B Vaccines (Basel). 2022; 10(11).

PMID: 36423003 PMC: 9699068. DOI: 10.3390/vaccines10111907.


Sequence Diversity of Tp1 and Tp2 Antigens and Population Genetic Analysis of in Unvaccinated Cattle in Zambia's Chongwe and Chisamba Districts.

Muleya W, Atuhaire D, Mupila Z, Mbao V, Mayembe P, Kalenga S Pathogens. 2022; 11(2).

PMID: 35215058 PMC: 8879479. DOI: 10.3390/pathogens11020114.


References
1.
Toye P, Goddeeris B, Iams K, Musoke A, Morrison W . Characterization of a polymorphic immunodominant molecule in sporozoites and schizonts of Theileria parva. Parasite Immunol. 1991; 13(1):49-62. DOI: 10.1111/j.1365-3024.1991.tb00262.x. View

2.
Baumgartner M, Tardieux I, Ohayon H, Gounon P, Langsley G . The use of nocodazole in cell cycle analysis and parasite purification from Theileria parva-infected B cells. Microbes Infect. 1999; 1(14):1181-8. DOI: 10.1016/s1286-4579(99)00244-0. View

3.
Preston P, Brown C, Richardson W . Cytokines inhibit the development of trophozoite-infected cells of Theileria annulata and Theileria parva but enhance the proliferation of macroschizont-infected cell lines. Parasite Immunol. 1992; 14(2):125-41. DOI: 10.1111/j.1365-3024.1992.tb00456.x. View

4.
McKeever D, Taracha E, Innes E, MacHugh N, Awino E, Goddeeris B . Adoptive transfer of immunity to Theileria parva in the CD8+ fraction of responding efferent lymph. Proc Natl Acad Sci U S A. 1994; 91(5):1959-63. PMC: 43284. DOI: 10.1073/pnas.91.5.1959. View

5.
Taracha E, Goddeeris B, Morzaria S, Morrison W . Parasite strain specificity of precursor cytotoxic T cells in individual animals correlates with cross-protection in cattle challenged with Theileria parva. Infect Immun. 1995; 63(4):1258-62. PMC: 173144. DOI: 10.1128/iai.63.4.1258-1262.1995. View